XML 37 R28.htm IDEA: XBRL DOCUMENT
v3.26.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Segment Reporting [Abstract] |
Schedule of segment revenue and expenses to consolidated net loss | The following table reconciles segment revenue and expenses to consolidated net loss for the three months ended March 31, 2026 and 2025 (in thousands):
|  | Three Months Ended March 31, |
|  | 2026 |  |  | 2025 |
Direct research and development expenses by program 1,2: |  |  |  |  |  |
Avexitide |  | $ | 9,990 |  |  | $ | 5,426 |
AMX0035 - PSP |  |  | 649 |  |  |  | 4,563 |
Other programs 3 |  |  | 7,977 |  |  |  | 3,772 |
Personnel-related research and development 4 |  |  | 8,994 |  |  |  | 8,358 |
Selling, general and administrative |  |  | 16,169 |  |  |  | 15,684 |
Interest income |  |  | (2,570 | ) |  |  | (2,231 | )
Other segment items 5 |  |  | 75 |  |  |  | 335 |
Net loss |  | $ | (41,284 | ) |  | $ | (35,907 | )
1. The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. As the Company has one reportable segment, there were no intersegment eliminations for the three months ended March 31, 2026 and 2025. 2. Depreciation and amortization expense of $0.1 million during the three months ended March 31, 2026, and $0.2 million during the three months ended March 31, 2025, are allocated across the significant expense captions. 3. Other programs includes milestone payments totaling $4.0 million made to Gubra following the selection and handover of AMX0318 as a development candidate for PBH and other rare diseases during the three months ended March 31, 2026. 4. The Company does not allocate personnel and other similar costs to specific programs because these costs are deployed across multiple programs. 5. Other segment items primarily consists of net realized and unrealized losses on foreign exchange transactions.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration